Research at the Molecular and circuit neuropharmacology – Gilberto Fisone group
Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder and is diagnosed based on the appearance of tremor, rigidity, and bradykinesia, secondary to the loss of midbrain dopamine neurons projecting to the basal ganglia. In addition to the cardinal motor symptoms, PD is accompanied by a wide range of co-morbidities, which include olfactory and sleep disturbances, affective disorders and cognitive impairment.
These conditions are often refractory to and may even be exacerbated by standard dopamine replacement therapies against PD. In addition, treatment with L-DOPA or dopamine receptor agonists is often accompanied by the development of motor complications, or dyskinesia, and obsessive-compulsive disorders, including pathological gambling and addictive-like behaviour.
Our work is based on the behavioral characterization of animal models reproducing these various disorders, combined with multiscale analyses to identify molecular, cellular and circuit abnormalities as potential targets for therapeutic interventions.
Research focus
Non-motor symptoms in Parkinson’s disease
A major research line centres on the non-motor comorbidities commonly observed in PD patients, which often appear during the prodromal phase of the disease.We have set up a toxin-based mouse model of early-stage PD, which reproduces several of these conditions.
For a detailed description, see Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson’s Disease for the Study of Non-Motor Symptoms.
We are currently using this model to investigate signaling and circuit abnormalities linked to anxiety and depression. Part of these studies are carried out within the AND-PD consortium, which is supported by the Horizon2020 EU program.
Other projects focus on circadian rhythm and sleep disorders, which are commonly observed in both de novo and medicated PD patients. Our mouse model of PD is characterized by disrupted rest/activity and endogenous circadian rhythm (see https://doi.org/10.1038/tp.2017.58). Using polysomnographic recording, we are examining whether these anomalies are accompanied by changes in sleep architecture, indicative of excessive day time sleepiness, sleep fragmentation, insomnia, and REM sleep behavior disorder.
Molecular mechanisms of L-DOPA-induced dyskinesia
Our laboratory has identified several signal transduction components of the cAMP, ERK and mTOR cascades causally linked to the dystonic and choreic uncontrollable movements (dyskinesia) developed in response to administration of L-DOPA.
Recently, we provided evidence in support of the involvement of impaired autophagy in L-DOPA-induced dyskinesia.
This finding suggests that autophagy promoting drugs, including those approved for the treatment of cancer and metabolic disorders, may also be utilized as anti-dyskinetic agents.
Obsessive compulsive disorders in Parkinson’s disease
We are optimizing a mouse model of PD reproducing obsessive-compulsive disorders associated with the administration of dopamine replacement therapy. Currently, we are examining the addictive-like properties of L-DOPA in a mouse model of PD, which reproduces a psychiatric complication affecting Parkinsonian patients and commonly referred to as dopamine-dysregulation syndrome. In other studies, we are setting up a machine-learning based approach to measure the impact of dopamine receptor agonists on stereotypic, repetitive behaviour.